<p>Radnor Capital Management LLC 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第四季度将其在西方制药服务公司（West Pharmaceutical Services, Inc.，NYSE:WST - 免费报告）的持股增加了 130.6%。该公司在此期间额外购买了 3,398 股后，持有该医疗器械供应商的 6,000 股股票。截至其最近向 SEC 提交的文件，Radnor Capital Management LLC 在西方制药服务公司的持股价值为 1,651,000 美元。</p>
<ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也对其在 WST 的持仓进行了调整。Empowered Funds LLC 在第一季度将其在西方制药服务公司的持仓增加了 16.1%。Empowered Funds LLC 现在拥有 1,611 股该医疗器械供应商的股票，价值为 361,000 美元，此前在上个季度购买了 224 股。Intech Investment Management LLC 在第一季度将其在西方制药服务公司的持仓增加了 27.7%。Intech Investment Management LLC 现在拥有 6,020 股该医疗器械供应商的股票，价值为 1,348,000 美元，此前在上个季度购买了 1,307 股。Acadian Asset Management LLC 在第一季度将其在西方制药服务公司的持仓增加了 14.1%。Acadian Asset Management LLC 现在拥有 1,271 股该医疗器械供应商的股票，价值为 284,000 美元，此前在上个季度购买了 157 股。EverSource Wealth Advisors LLC 在第二季度将其在西方制药服务公司的持仓增加了 78.2%。EverSource Wealth Advisors LLC 现在拥有 449 股该医疗器械供应商的股票，价值为 98,000 美元，此前在上个季度购买了 197 股。最后，First Trust Advisors LP 在第二季度将其在西方制药服务公司的持仓增加了 168.4%。First Trust Advisors LP 现在拥有 46,332 股该医疗器械供应商的股票，价值为 10,137,000 美元，此前在上个季度购买了 29,067 股。93.90% 的股票由机构投资者持有。</p>
<h2>西方制药服务股价上涨 0.5%</h2>
<p>WST 周二开盘价为 304.31 美元。该股票的市值为 215 亿美元，市盈率为 40.68，市盈率/增长比率为 2.53，贝塔值为 1.17。西方制药服务公司在过去 12 个月的最低价为 203.74 美元，最高价为 330.88 美元。该公司的 50 日简单移动平均线为 269.91 美元，200 日简单移动平均线为 265.43 美元。该公司的流动比率为 2.71，速动比率为 2.04，债务与股本比率为 0.07。</p>
<ul>
<li>什么因素将推动标普 500 今年的表现？</li>
</ul>
<p>西方制药服务（NYSE:WST - 获取免费报告）最近在 4 月 23 日发布了季度财报。该医疗器械供应商报告季度每股收益（EPS）为 2.13 美元，超出市场共识预期的 1.68 美元，超出幅度为 0.45 美元。该公司季度收入为 8.449 亿美元，超过分析师预期的 7.7968 亿美元。西方制药服务的净利润率为 16.85%，股本回报率为 19.03%。该公司的收入较去年同期增长了 21.0%。在去年同期，该公司每股收益为 1.45 美元。西方制药服务已将其 2026 财年的指导目标设定为 8.400-8.750 美元的每股收益，并将其 2026 年第二季度的指导目标设定为 2.050-2.120 美元的每股收益。整体来看，研究分析师预计西方制药服务公司在当前财年将发布 8.61 美元的每股收益。</p>
<p>西方制药服务宣布其董事会于 2 月 17 日启动了一项股票回购计划，允许公司回购 10 亿美元的流通股。该回购授权允许该医疗器械供应商通过公开市场购买最多 5.6% 的股票。股票回购计划通常表明公司的管理层认为其股票被低估。</p>
<h2>西方制药服务的内部买卖</h2>
<ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
<p>在相关消息中，副总裁 Annette F. Favorite 于 4 月 27 日星期一出售了 2,817 股公司的股票。该股票以 305.20 美元的平均价格出售，总价值为 859,748.40 美元。出售后，副总裁直接持有公司 16,828 股股票，价值约为 5,135,905.60 美元。此次交易使其持仓减少了 14.34%。该交易已在向 SEC 的法律文件中披露，可以通过此超链接访问。此外，首席会计官 Chad Winters 于 4 月 27 日星期一出售了 896 股公司的股票。该股票以 300.67 美元的平均价格出售，总交易额为 269,400.32 美元。出售完成后，首席会计官直接持有公司 1,523 股，价值为 457,920.41 美元。这代表其持股减少了 37.04%。该销售的 SEC 文件提供了更多信息。内部人士持有公司 0.60% 的股票。</p>
<h2>分析师评级变动</h2>
<p>WST 最近成为多份分析师报告的主题。Evercore 在 4 月 24 日的研究报告中重新给予西方制药服务公司 &#34;跑赢大盘&#34; 的评级。德意志银行在 2 月 13 日的研究报告中重新给予西方制药服务公司 &#34;买入&#34; 的评级，并设定了 315.00 美元的目标价。摩根士丹利在 4 月 27 日的研究报告中设定了西方制药服务公司的 315.00 美元目标价。花旗集团在 4 月 24 日的研究报告中重新给予西方制药服务公司 &#34;买入&#34; 的评级。最后，瑞银集团在 2 月 13 日的研究报告中重新给予西方制药服务公司 &#34;买入&#34; 的评级，并设定了 340.00 美元的目标价。两位股票研究分析师给予该股票 &#34;强烈买入&#34; 的评级，七位给予 &#34;买入&#34; 的评级，三位给予 &#34;持有&#34; 的评级。根据 MarketBeat.com 的数据，该公司的共识评级为 &#34;适度买入&#34;，共识目标价为 322.89 美元。</p>
<p><strong>查看我们关于西方制药服务公司的最新股票报告</strong></p>
<h2>西方制药服务公司简介</h2>
<p>（免费报告）</p>
<p>西方制药服务公司是一家全球开发和制造组件、系统及服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专用药物输送设备。西方以其保持无菌性和与敏感药物配方兼容的弹性封闭件、密封件和聚合物组件而闻名。</p>
<p>除了组件制造，西方还提供工程化输送系统和产品生命周期支持服务。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比西方制药服务公司更好的股票</li>
<li>为什么应用光电子股票可能接近转折点</li>
<li>从高收益到高增长：3 只提升股息的股票</li>
<li>Everspin Technologies 是否是下一个 AI 边缘突破？</li>
<li>5 只机器人股票值得关注，因为物理 AI 正在积聚势头</li>
</ul>
<p><strong>想看看其他对 WST 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取西方制药服务公司（NYSE:WST - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在西方制药服务公司吗？</h2>
<p>在你考虑西方制药服务公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而西方制药服务公司并不在名单上。</p>
<p>虽然西方制药服务公司目前在分析师中获得 &#34;适度买入&#34; 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西氏医药服务

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>Radnor Capital Management LLC 在第四季度将其在西氏医药服务（West Pharmaceutical Services, Inc.，NYSE:WST）的持股增加了 130.6%，目前持有 6,000 股，价值 165 万美元。其他机构投资者也提高了他们的持仓。西氏医药的股票开盘价为 304.31 美元，市值为 215 亿美元，市盈率为 40.68。该公司报告了强劲的收益，超出预期，并宣布了一项 10 亿美元的股票回购计划</p>

<p>Radnor Capital Management LLC boosted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 130.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 6,000 shares of the medical instruments supplier's stock after acquiring an additional 3,398 shares during the period. Radnor Capital Management LLC's holdings in West Pharmaceutical Services were worth $1,651,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>Radnor Capital Management LLC 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第四季度将其在西方制药服务公司（West Pharmaceutical Services, Inc.，NYSE:WST - 免费报告）的持股增加了 130.6%。该公司在此期间额外购买了 3,398 股后，持有该医疗器械供应商的 6,000 股股票。截至其最近向 SEC 提交的文件，Radnor Capital Management LLC 在西方制药服务公司的持股价值为 1,651,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently made changes to their positions in WST. Empowered Funds LLC boosted its position in shares of West Pharmaceutical Services by 16.1% during the first quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier's stock worth $361,000 after purchasing an additional 224 shares in the last quarter. Intech Investment Management LLC boosted its position in shares of West Pharmaceutical Services by 27.7% during the first quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier's stock worth $1,348,000 after purchasing an additional 1,307 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of West Pharmaceutical Services by 14.1% during the first quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier's stock worth $284,000 after purchasing an additional 157 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of West Pharmaceutical Services by 78.2% during the second quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier's stock worth $98,000 after purchasing an additional 197 shares in the last quarter. Finally, First Trust Advisors LP boosted its position in shares of West Pharmaceutical Services by 168.4% during the second quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier's stock worth $10,137,000 after purchasing an additional 29,067 shares in the last quarter. 93.90% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也对其在 WST 的持仓进行了调整。Empowered Funds LLC 在第一季度将其在西方制药服务公司的持仓增加了 16.1%。Empowered Funds LLC 现在拥有 1,611 股该医疗器械供应商的股票，价值为 361,000 美元，此前在上个季度购买了 224 股。Intech Investment Management LLC 在第一季度将其在西方制药服务公司的持仓增加了 27.7%。Intech Investment Management LLC 现在拥有 6,020 股该医疗器械供应商的股票，价值为 1,348,000 美元，此前在上个季度购买了 1,307 股。Acadian Asset Management LLC 在第一季度将其在西方制药服务公司的持仓增加了 14.1%。Acadian Asset Management LLC 现在拥有 1,271 股该医疗器械供应商的股票，价值为 284,000 美元，此前在上个季度购买了 157 股。EverSource Wealth Advisors LLC 在第二季度将其在西方制药服务公司的持仓增加了 78.2%。EverSource Wealth Advisors LLC 现在拥有 449 股该医疗器械供应商的股票，价值为 98,000 美元，此前在上个季度购买了 197 股。最后，First Trust Advisors LP 在第二季度将其在西方制药服务公司的持仓增加了 168.4%。First Trust Advisors LP 现在拥有 46,332 股该医疗器械供应商的股票，价值为 10,137,000 美元，此前在上个季度购买了 29,067 股。93.90% 的股票由机构投资者持有。</p>
</div><h2>West Pharmaceutical Services Trading Up 0.5%</h2>
<div class="lb-trans"><h2>西方制药服务股价上涨 0.5%</h2>
</div><p>WST opened at $304.31 on Tuesday. The stock has a market capitalization of $21.50 billion, a P/E ratio of 40.68, a P/E/G ratio of 2.53 and a beta of 1.17. West Pharmaceutical Services, Inc. has a 12 month low of $203.74 and a 12 month high of $330.88. The firm's fifty day simple moving average is $269.91 and its 200 day simple moving average is $265.43. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07.</p>
<div class="lb-trans"><p>WST 周二开盘价为 304.31 美元。该股票的市值为 215 亿美元，市盈率为 40.68，市盈率/增长比率为 2.53，贝塔值为 1.17。西方制药服务公司在过去 12 个月的最低价为 203.74 美元，最高价为 330.88 美元。该公司的 50 日简单移动平均线为 269.91 美元，200 日简单移动平均线为 265.43 美元。该公司的流动比率为 2.71，速动比率为 2.04，债务与股本比率为 0.07。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>什么因素将推动标普 500 今年的表现？</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, beating the consensus estimate of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to analysts' expectations of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm's revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, research analysts anticipate that West Pharmaceutical Services, Inc. will post 8.61 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>西方制药服务（NYSE:WST - 获取免费报告）最近在 4 月 23 日发布了季度财报。该医疗器械供应商报告季度每股收益（EPS）为 2.13 美元，超出市场共识预期的 1.68 美元，超出幅度为 0.45 美元。该公司季度收入为 8.449 亿美元，超过分析师预期的 7.7968 亿美元。西方制药服务的净利润率为 16.85%，股本回报率为 19.03%。该公司的收入较去年同期增长了 21.0%。在去年同期，该公司每股收益为 1.45 美元。西方制药服务已将其 2026 财年的指导目标设定为 8.400-8.750 美元的每股收益，并将其 2026 年第二季度的指导目标设定为 2.050-2.120 美元的每股收益。整体来看，研究分析师预计西方制药服务公司在当前财年将发布 8.61 美元的每股收益。</p>
</div><p>West Pharmaceutical Services announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, February 17th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 5.6% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its shares are undervalued.</p>
<div class="lb-trans"><p>西方制药服务宣布其董事会于 2 月 17 日启动了一项股票回购计划，允许公司回购 10 亿美元的流通股。该回购授权允许该医疗器械供应商通过公开市场购买最多 5.6% 的股票。股票回购计划通常表明公司的管理层认为其股票被低估。</p>
</div><h2>Insider Buying and Selling at West Pharmaceutical Services</h2>
<div class="lb-trans"><h2>西方制药服务的内部买卖</h2>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
</div><p>In related news, VP Annette F. Favorite sold 2,817 shares of the business's stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the sale, the vice president directly owned 16,828 shares of the company's stock, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Chad Winters sold 896 shares of the business's stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the sale, the chief accounting officer directly owned 1,523 shares in the company, valued at $457,920.41. This represents a 37.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.60% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，副总裁 Annette F. Favorite 于 4 月 27 日星期一出售了 2,817 股公司的股票。该股票以 305.20 美元的平均价格出售，总价值为 859,748.40 美元。出售后，副总裁直接持有公司 16,828 股股票，价值约为 5,135,905.60 美元。此次交易使其持仓减少了 14.34%。该交易已在向 SEC 的法律文件中披露，可以通过此超链接访问。此外，首席会计官 Chad Winters 于 4 月 27 日星期一出售了 896 股公司的股票。该股票以 300.67 美元的平均价格出售，总交易额为 269,400.32 美元。出售完成后，首席会计官直接持有公司 1,523 股，价值为 457,920.41 美元。这代表其持股减少了 37.04%。该销售的 SEC 文件提供了更多信息。内部人士持有公司 0.60% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>WST has been the topic of a number of recent analyst reports. Evercore reissued an &#34;outperform&#34; rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Deutsche Bank Aktiengesellschaft reissued a &#34;buy&#34; rating and set a $315.00 price target on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Morgan Stanley set a $315.00 price target on shares of West Pharmaceutical Services in a research report on Monday, April 27th. Citigroup reissued a &#34;buy&#34; rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Finally, UBS Group reissued a &#34;buy&#34; rating and set a $340.00 price target on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $322.89.</p>
<div class="lb-trans"><p>WST 最近成为多份分析师报告的主题。Evercore 在 4 月 24 日的研究报告中重新给予西方制药服务公司 &#34;跑赢大盘&#34; 的评级。德意志银行在 2 月 13 日的研究报告中重新给予西方制药服务公司 &#34;买入&#34; 的评级，并设定了 315.00 美元的目标价。摩根士丹利在 4 月 27 日的研究报告中设定了西方制药服务公司的 315.00 美元目标价。花旗集团在 4 月 24 日的研究报告中重新给予西方制药服务公司 &#34;买入&#34; 的评级。最后，瑞银集团在 2 月 13 日的研究报告中重新给予西方制药服务公司 &#34;买入&#34; 的评级，并设定了 340.00 美元的目标价。两位股票研究分析师给予该股票 &#34;强烈买入&#34; 的评级，七位给予 &#34;买入&#34; 的评级，三位给予 &#34;持有&#34; 的评级。根据 MarketBeat.com 的数据，该公司的共识评级为 &#34;适度买入&#34;，共识目标价为 322.89 美元。</p>
</div><p><strong>View Our Latest Stock Report on West Pharmaceutical Services</strong></p>
<div class="lb-trans"><p><strong>查看我们关于西方制药服务公司的最新股票报告</strong></p>
</div><h2>West Pharmaceutical Services Company Profile</h2>
<div class="lb-trans"><h2>西方制药服务公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.</p>
<div class="lb-trans"><p>西方制药服务公司是一家全球开发和制造组件、系统及服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专用药物输送设备。西方以其保持无菌性和与敏感药物配方兼容的弹性封闭件、密封件和聚合物组件而闻名。</p>
</div><p>In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.</p>
<div class="lb-trans"><p>除了组件制造，西方还提供工程化输送系统和产品生命周期支持服务。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>Why Applied Optoelectronics Stock May Be Near a Turning Point</li>
<li>From High-Yield to High-Growth: 3 Stocks Boosting Dividends</li>
<li>Is Everspin Technologies the Next AI Edge Breakout?</li>
<li>5 Robotics Stocks to Watch as Physical AI Builds Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比西方制药服务公司更好的股票</li>
<li>为什么应用光电子股票可能接近转折点</li>
<li>从高收益到高增长：3 只提升股息的股票</li>
<li>Everspin Technologies 是否是下一个 AI 边缘突破？</li>
<li>5 只机器人股票值得关注，因为物理 AI 正在积聚势头</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding WST?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 WST 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取西方制药服务公司（NYSE:WST - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在西方制药服务公司吗？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑西方制药服务公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而西方制药服务公司并不在名单上。</p>
</div><p>While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然西方制药服务公司目前在分析师中获得 &#34;适度买入&#34; 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

Market Beat

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

Arcadian Asset

标普 500 指数

Radnor Capital Management LLC 持有西氏医药服务公司价值 165 万美元的股票。$WST